TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Extended-Release Naltrexone for Opioid Relapse Prevention Following Release From Jail
Brief Summary: This pilot study's primary aim is to compare rates of sustained opioid relapse, defined as self-reported opioid use \>50% (\>15 of 30) of days during the first 30 days following release from jail, among persons treated with XR-NTX pre-release vs. controls not receiving XR-NTX.


Options:
A: Inclusion Criteria:

* Women aged 18-64 years
* Patients at the health care site
* Able to participate in English
* Able to separate from accompanying person(s)

Exclusion Criteria:

* Too ill to participate
* Unable to separate from accompanying person(s)
* Unable to speak, read, or write English
B: Inclusion Criteria:

* 18 to 70 years patients needing methadone for their opioid dependence who are either naives of methadone treatment (prescribed) since at least 1 month
* need to switch from buprenorphine to methadone treatment
* negative test for pregnancy

Exclusion Criteria:

* co-dependent on alcohol and benzodiazepines,
* inmates,
* pregnant women,
* individual in irregular situation or who cannot be joined by phone.
C: Inclusion Criteria:

* Adults incarcerated in NYC jails with known release date
* DSM-IV criteria for current opioid dependence
* No current agonist (methadone, buprenorphine) treatment
* Currently opioid free by history ('detoxed') and with a negative urine for all opioids
* General good health as determined by complete medical interview and physical examination
* Age 18-60 years.

Exclusion Criteria:

* History of liver failure, cirrhosis, or recent liver function test levels greater than three times normal
* Pregnancy, lactation, or planning conception
* Active medical illness that might make participation hazardous
* Untreated psychiatric disorder
* History of allergic reaction to naltrexone, PLG (polylactide co-glycolide), carboxymethylcellulose, or any other components of the diluent.
* Current chronic pain condition treated with opioids.
D: Inclusion Criteria:

1. Parolees enrolled in Amity's Amistad's program;
2. Age 18-60;
3. Discharged from prison or jail within the last six months;
4. History of drug use 12 months prior to most recent incarceration;
5. Previously homeless prior to most recent incarceration; and
6. Willing to provide informed consent

Exclusion Criteria:

1. Monolingual speakers of languages other than English; and
2. Persons judged to be cognitively impaired by the research staff.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dietary Supply of Docosahexaenoic Acid (DHA) and 5-methyl-tetrahydro-folate (MTHF) During the Second Half of Pregnancy and Early Infancy
Brief Summary: Pregnant women are randomised to supplementation with fish oil, methyl tetrahydro folic acid, both or a placebo during the second half of pregnancy. Biochemical measures are determined in maternal blood during pregnancy and in cord blood.

Non invasive follow up examinations of infants at ages 4, 5.5, 6.5, 7.5, 8, 9 and 9.5 years focus on long term effects of supplementation anthropometric development, neurological development and allergy risk.


Options:
A: Inclusion Criteria:

1. Consent
2. mother with normal gestation.

Exclusion Criteria:

1. Risk factors during gestation.
2. Lactose intolerance
3. systemic illness.
4. Kwashiorkor.
5. Metabolic illness.
6. Foetal pathologies
B: Inclusion Criteria:

* Gestational age \<= 15th week of gestation
* Age: 18-43 years
* Written informed consent
* Body mass index (BMI) before pregnancy between 18 and 30 km/m2

Exclusion Criteria:

* High risk pregnancy
* Hypertonus
* Chronic diseases (i.e. diabetes mellitus)
* Psychiatric diseases
* Former supplementation with LC-PUFA
C: Inclusion Criteria:

* singleton pregnancy
* gestation \<20 week at enrollment
* intention to deliver in one of the study centers
* body weight at time of enrollment from 50 kg to 92 kg

Exclusion Criteria:

* serious chronic illness (eg, diabetes, hepatitis)
* use fish oil supplements since the beginning of pregnancy
* use of folate or vitamin B-12 supplements after gestation week 16
D: Inclusion Criteria (mother):

* Pregnant women
* Living in Sealand, Denmark
* Fluent in Danish Language
* Willing to let the newborn child participate in the study

Exclusion Criteria (mother):

* Participating in other clinical trial

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dietary Supply of Docosahexaenoic Acid (DHA) and 5-methyl-tetrahydro-folate (MTHF) During the Second Half of Pregnancy and Early Infancy
Brief Summary: Pregnant women are randomised to supplementation with fish oil, methyl tetrahydro folic acid, both or a placebo during the second half of pregnancy. Biochemical measures are determined in maternal blood during pregnancy and in cord blood.

Non invasive follow up examinations of infants at ages 4, 5.5, 6.5, 7.5, 8, 9 and 9.5 years focus on long term effects of supplementation anthropometric development, neurological development and allergy risk.


Options:
A: Inclusion Criteria:

* Gestational age \<= 15th week of gestation
* Age: 18-43 years
* Written informed consent
* Body mass index (BMI) before pregnancy between 18 and 30 km/m2

Exclusion Criteria:

* High risk pregnancy
* Hypertonus
* Chronic diseases (i.e. diabetes mellitus)
* Psychiatric diseases
* Former supplementation with LC-PUFA
B: Inclusion Criteria:

* 18-22 weeks pregnant (based on last menstrual period)
* 18 - 35 years old
* Resident of Cuernavaca who intends to deliver at the IMSS General Hospital I and remain in the area for the 2 years following recruitment
* Intends to predominantly breastfeed infant until 3 months of age
* Agrees to participate with informed consent

Exclusion criteria

* High risk pregnancy: If documented in the clinical record at recruitment and will include history and prevalence of abruptio placentae, any serious bleeding episode in the current pregnancy, gestational diabetes, pregnancy induced hypertension, maternal toxoplasmosis infection during pregnancy, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use.
* Lipid metabolism (hyperlipidemia) and/or absorption disorders
* Regular intake of fish oil or DHA supplements during pregnancy
* Chronic use of medication for illnesses like epilepsy
C: Inclusion Criteria:

* Pregnant 8-20 wks at enrollment
* single fetus
* BMI \<40

Exclusion Criteria:

* diabetes (Type I, ii, GDM)
* hypertension (primary, PIH, preeclampsia/eclampsia)
D: Inclusion Criteria:

* singleton pregnancy
* gestation \<20 week at enrollment
* intention to deliver in one of the study centers
* body weight at time of enrollment from 50 kg to 92 kg

Exclusion Criteria:

* serious chronic illness (eg, diabetes, hepatitis)
* use fish oil supplements since the beginning of pregnancy
* use of folate or vitamin B-12 supplements after gestation week 16

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns
Brief Summary: This application a phase II clinical trial to address the possible active mechanisms of probiotics and to obtain preliminary efficacy and safety data after the administration of a probiotic, Lactobacillus reuteri a population of premature infants.

The hypothesis is that the exogenous supplementation Lactobacillus reuteri to premature infants will lead to clinical beneficial effects by modifying their intestinal microbiota and enhancing their intestinal immunological response.


Options:
A: Inclusion Criteria:

* Patients eligible for enrollment will include all pediatric patients suffering from HD at an age of 12 months or younger. All patients will require consent by either parent or adult guardian

Exclusion Criteria:

* Patients will be excluded if children that are deemed hemodynamically unstable and require immediate operative intervention, age more than one year of age, as this may mean very delay in diagnosis and may affect the study results, or infants having major congenital anomalies with short life expectancy. Additional exclusion criteria are those patients' parents or adult guardian who refuse to undergo randomization. Finally, those children who are transferred to another non-participating hospital will be excluded.
B: Inclusion Criteria:

* Gastroschisis
* Born at or transferred to UC Davis Children's hospital

Exclusion Criteria:

* None
C: Inclusion Criteria:

* Preterm newborns admitted to the neonatal intensive care units with a birth weight 700-1500 g and who survive more than 3 days

Exclusion Criteria:

* Chromosomal anomalies.
* Major congenital anomalies (complex cardiac anomalies, congenital hydrocephalus, renal dysplasia)
* Congenital (e.g. jejunal atresia) and acquired (e.g. GI perforation) gastrointestinal pathology precluding oral feed and/or requiring major surgical or medical intervention
* Parental refusal
* Prior enrollment into a conflicting clinical trial
D: Inclusion Criteria:

* Weight between 800 - 1500g
* Tolerating enteral feeding within 48 hours
* Having obtained his/her parents or legal representative informed consent

Exclusion Criteria:

* Chromosomal abnormality
* Hydrops featalis
* Congenital malformation of the gastrointestinal tract
* Congenital heart defects or other major congenital abnormalities likely to affect feeding and/or feeding tolerance
* Currently participating in another clinical trial

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns
Brief Summary: This application a phase II clinical trial to address the possible active mechanisms of probiotics and to obtain preliminary efficacy and safety data after the administration of a probiotic, Lactobacillus reuteri a population of premature infants.

The hypothesis is that the exogenous supplementation Lactobacillus reuteri to premature infants will lead to clinical beneficial effects by modifying their intestinal microbiota and enhancing their intestinal immunological response.


Options:
A: Inclusion Criteria:

* Weight between 800 - 1500g
* Tolerating enteral feeding within 48 hours
* Having obtained his/her parents or legal representative informed consent

Exclusion Criteria:

* Chromosomal abnormality
* Hydrops featalis
* Congenital malformation of the gastrointestinal tract
* Congenital heart defects or other major congenital abnormalities likely to affect feeding and/or feeding tolerance
* Currently participating in another clinical trial
B: Inclusion Criteria:

* Preterm newborns admitted to the neonatal intensive care units with a birth weight 700-1500 g and who survive more than 3 days

Exclusion Criteria:

* Chromosomal anomalies.
* Major congenital anomalies (complex cardiac anomalies, congenital hydrocephalus, renal dysplasia)
* Congenital (e.g. jejunal atresia) and acquired (e.g. GI perforation) gastrointestinal pathology precluding oral feed and/or requiring major surgical or medical intervention
* Parental refusal
* Prior enrollment into a conflicting clinical trial
C: Inclusion Criteria:

* VLBW infants admitted to NICU at the first 7 days of life

Exclusion Criteria:

* expected life lower than 7 days,
* babies who could not be fed (any metabolic disorders, gastrointestinal system surgical disorders etc.),
* severe asphyxia,
* severe congenital anomaly
D: Inclusion Criteria:

* Cyanotic congenital heart disease
* infants \>35 weeks of gestational age
* Born at or transferred to Sami Ulus CH

Exclusion Criteria:

* Congenital anomalies of the intestinal tract

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns
Brief Summary: This application a phase II clinical trial to address the possible active mechanisms of probiotics and to obtain preliminary efficacy and safety data after the administration of a probiotic, Lactobacillus reuteri a population of premature infants.

The hypothesis is that the exogenous supplementation Lactobacillus reuteri to premature infants will lead to clinical beneficial effects by modifying their intestinal microbiota and enhancing their intestinal immunological response.


Options:
A: Inclusion Criteria:

* Very low birth weight infants \< 1500 gr

Exclusion Criteria:

* Genetic anomalies
* Not willing to participate
* Allergy to S. boulardii components
B: Inclusion Criteria:

* Infants with birth weight less than 1500g

Exclusion Criteria:

* Sever bacteremia
* Congenital anomaly
* Not suitable for the trial defined by an attending neonatologist
C: Inclusion Criteria:

* Preterm newborns admitted to the neonatal intensive care units with a birth weight 700-1500 g and who survive more than 3 days

Exclusion Criteria:

* Chromosomal anomalies.
* Major congenital anomalies (complex cardiac anomalies, congenital hydrocephalus, renal dysplasia)
* Congenital (e.g. jejunal atresia) and acquired (e.g. GI perforation) gastrointestinal pathology precluding oral feed and/or requiring major surgical or medical intervention
* Parental refusal
* Prior enrollment into a conflicting clinical trial
D: Inclusion Criteria:

* Weight between 800 - 1500g
* Tolerating enteral feeding within 48 hours
* Having obtained his/her parents or legal representative informed consent

Exclusion Criteria:

* Chromosomal abnormality
* Hydrops featalis
* Congenital malformation of the gastrointestinal tract
* Congenital heart defects or other major congenital abnormalities likely to affect feeding and/or feeding tolerance
* Currently participating in another clinical trial

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Pilot Study to Evaluate the Effects of Lactobacillus Reuteri in Preterm Newborns
Brief Summary: This application a phase II clinical trial to address the possible active mechanisms of probiotics and to obtain preliminary efficacy and safety data after the administration of a probiotic, Lactobacillus reuteri a population of premature infants.

The hypothesis is that the exogenous supplementation Lactobacillus reuteri to premature infants will lead to clinical beneficial effects by modifying their intestinal microbiota and enhancing their intestinal immunological response.


Options:
A: Inclusion Criteria:

* gestational age≤32 weeks and birthweight ≤1250 gr, and \<48 hours postnatal age

Exclusion Criteria:

* Major congenital and/or chromosomal anomaly, Cyanotic congenital heart disease, Asphyxiated birth with pH \<7.0 and base deficit ≥16mmol/l Severe cardiopulmonary compromise or multiorgan failure Twin-twin transfusion, Those died in postnatal 5 days of age
B: Inclusion Criteria:

* Preterm newborns admitted to the neonatal intensive care units with a birth weight 700-1500 g and who survive more than 3 days

Exclusion Criteria:

* Chromosomal anomalies.
* Major congenital anomalies (complex cardiac anomalies, congenital hydrocephalus, renal dysplasia)
* Congenital (e.g. jejunal atresia) and acquired (e.g. GI perforation) gastrointestinal pathology precluding oral feed and/or requiring major surgical or medical intervention
* Parental refusal
* Prior enrollment into a conflicting clinical trial
C: Inclusion Criteria:

* admission to the NICU within 48 hours with gestational age between 22.0 and 28.6 weeks

Exclusion Criteria:

* small for gestational age (\<10th percentile birthweight), major congenital or chromosomal anomalies, and infants with terminal illness in which decision to withhold or limit support have been made
D: Inclusion Criteria:

* Very low birth weight infants \< 1500 gr

Exclusion Criteria:

* Genetic anomalies
* Not willing to participate
* Allergy to S. boulardii components

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Trial of Pre-Pregnancy Supplements
Brief Summary: The purpose of this study is to determine whether daily oral supplements of multivitamins (including vitamins B-complex, C and E) along with Iron and folic acid given to non-pregnant women results in lower prevalence of anemia in preparation for pregnancy when compared to daily iron and folic acid supplements or folic acid alone.


Options:
A: Inclusion Criteria:

* Positive stool sample for rotavirus test

Exclusion Criteria:

* Severe malnourishment
* Severe dehydration
* Use of antibiotics, probiotics or nitazoxanide 2 weeks before admission
* Systemic infections
* Severe chronic disease
* Mixed enteric infections besides rotavirus
B: Inclusion Criteria:

* Generally healthy subjects.

Exclusion Criteria:

* The presence of any chronic disease, pregnancy or lactation were considered as exclusion criteria.
C: Inclusion Criteria:

* potential blood donors with hemoglobin of at least 12.5 gm/dL
* no blood donation for at least 4 months
* successful donation of a unit of whole blood

Exclusion Criteria:

* individuals who are taking iron supplements including multivitamins containing iron and refuse to stop do so for the 24 weeks of the study.
* baseline ferritin \>300 ug/L (to exclude individuals with hemochromatosis)
D: Inclusion Criteria:

1. Girls aged \> =15 years and \<= 29 years
2. Have not missed a menstrual period during recruitment (no amenorrhea)
3. Has not been pregnant or given birth within the last 6 months
4. Intend to stay in the study area for at least 6 months after enrollment
5. Have provided written informed consent

Exclusion Criteria:

1. Amenorrhea or confirmed pregnancy at screening or enrollment.
2. Has given birth within 6 months
3. Already taking long-term vitamin supplementation.
4. Any severe illness requiring hospitalization at screening or enrollment (women who have been deemed to have recovered will be eligible once they return home).

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Randomized Trial of Home Versus Clinic-based Screening for Sexually Transmitted Infections in Long-Acting Reversible Contraceptive Users
Brief Summary: This study randomizes women using long-acting reversible methods of contraception to home-based STD screening through the mail compared to screening available in a clinical setting. We hypothesize that women randomized to home-based screening will be more likely to complete screening.


Options:
A: Inclusion Criteria:

* Participant in Contraceptive CHOICE cohort study
* Using a long-acting reversible method of contraception
* Completed baseline clinical survey in the Contraceptive CHOICE cohort study

Exclusion Criteria:

* Living outside the United States at time of annual STI screening
B: Inclusion Criteria: age 15 to 29, 2 or more risk factors for STDs, sexually active -

Exclusion Criteria: currently pregnant, homeless

-
C: Inclusion Criteria:

* All persons in the population register in Rogaland County from 18-25 years of age (born between 1/1-1980 - 31/12 -1987) registered 01.11.05. Per 11.11.2005 the size of this population was 41 793. The age cut off is decided because this is the age group with the highest incidence of Chlamydia infections.

Exclusion Criteria:

* All persons in the population register in Rogaland born between 1/1-1980 - 31/12 -1987 registered as:

  * living abroad (including Svalbard) - 6 persons
  * without (permanent) address - 49 persons
  * with client address- 6 persons with secret adress - 16 persons
  * military - 1 person

In total 78 persons were excluded
D: Inclusion Criteria:

* Women/girls with a lab-confirmed genital chlamydia infection

Exclusion Criteria:

* Women who are pregnant, or are trying to conceive in the following 3 months.
* Women who are planning to move in the following 3 months or currently living outside the study areas.
* Inability to understand spoken English adequately to assure informed consent and compliance with study procedures.
* Self-reported HIV infection; other serious illnesses or disability.
* Self-reported allergy to macrolide antibiotics such as azithromycin.
* Referrals from providers or clinics other than the STD or family planning clinics, unless women are re-tested at the STD clinics and test positive for chlamydia.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation
Brief Summary: The objectives of this study are to test if hypoxia in muscle tissue is an important factor contributing to clinical symptoms in chronic rheumatic muscle inflammation and to evaluate if a 12 week endurance exercise program will improve muscle tissue hypoxia and disability in patients with chronic rheumatic muscle inflammation.


Options:
A: Inclusion Criteria:

* formal diagnosis of muscular disease, either FascioScapuloHumeral Dystrophy (FSHD), Inclusion Body Myositis (IBM), Mitochondrial Myopathy (MM) or any other;
* being severely fatigued
* being cardiopulmonary stable and capable of aerobic training (as determined using a submaximal cycling exercise test with ECG (electrocardiography) and advice from a consultant cardiologist and pulmonologist);
* being motivated, committed to the program, and 'ready to change' which is discussed with the patient during the screening by a rehabilitation physician and an occupational therapist; to this end, motivational interviewing will be used (including a advantages/disadvantages matrix; a visual analogue scale (VAS) to rate the importance of participation in de program; and a VAS to rate the confidence a patient has that participation in the program is feasible)
* being able to formulate at least 3 individual participation goals during the interview with the occupational therapist.

Exclusion Criteria:

* active depression or other psychiatric disorder as indicated by a consultant psychologist or by the medical history,
* pregnancy,
* severe co-morbid condition,
* having participated in the Energetic program before
* a travel distance perceived as too burdensome
B: Inclusion Criteria:

* Danish patients with gene verified congenital myopathy

Exclusion Criteria:

* Patients who are to week to train at a cycle-ergometer for 10 weeks
* Patients who have other health issues, which can disturb the interpretation of the efficacy
C: Inclusion Criteria:

* Physically inactive
* Stable drugs regime for at least three months

Exclusion Criteria:

* Other rheumatic diseases
* Physical disability that prevent the patient to perform the physical tests
* Severe pulmonary disease
D: Inclusion Criteria:

* Patients with chronic, stable polymyositis or dermatomyositis with diagnosis of definite or probable polymyositis or dermatomyositis (Bohan and Peter 1975)
* Age 18-80 years
* Duration since diagnosis \> 6 months
* Exercising \< once a week,
* Stable disease activity and medication for at least one month.

Ten healthy controls matched for age, gender and physical exercise level will be included.

-

Exclusion Criteria:

* Severe pulmonary fibrosis
* Heart or lung conditions that contraindicate vigorous exercise
* Severe osteoporosis
* Not being able to perform the exercise program.

Answer: D